Immunological profiling of a panel of human ovarian cancer cell lines

Cancer Immunology, Immunotherapy

Volumn 57, Issue 1, 2008, Pages 31-42

  Carr, Tiffany M ^a   Adair, Sara J ^a   Fink, Mitsú J ^a   Hogan, Kevin T ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cancer antigens; Class I MHC molecules; Cytokine; Immune suppression; Ovarian cancer

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRUCTOSE BISPHOSPHATASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE (NADP); INTERLEUKIN 10; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 12; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MELANOMA ANTIGEN 6; NERVE CELL ADHESION MOLECULE; NY ESO 1 ANTIGEN; TAG 1; TAG 2A; TAG 2B; TAG 2C; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENDOMETRIOID CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMAN CELL; OVARY ADENOCARCINOMA; OVARY CANCER; OVARY CELL CULTURE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION;

EID: 35748979692     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0347-7     Document Type: Article

References (66)

1. Ahmadzadeh M, Rosenberg SA (2005) TGF-β1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 174:5215-5223
2. Akdis CA, Blaser K, Akdis CA, Blaser K (2001) Mechanisms of interleukin-10-mediated immune suppression. Immunology 103:131-136
3. Angus B, Purvis J, Stock D, Westley BR, Samson ACR, Routledge EG, Carpenter FH, Horne CHW (1987) NCL-5D3: a new monoclonal antibody recognizing low molecular weight cytokeratins effective for immunohistochemistry using fixed paraffin-embedded tissue. J Pathol 153:377-384
4. Babcock B, Anderson BW, Papayannopoulos I, Castilleja A, Murray JL, Stifani S, Kudelka AP, Wharton JT, Ioannides CG (1998) Ovarian and breast cytotoxic T lymphocytes can recognize peptides from the amino enhancer of split protein of the notch complex. Mol Immunol 35:1121-1133
5. Bartlett JM, Langdon SP, Scott WN, Love SB, Miller EP, Katsaros D, Smyth JF, Miller WR (1997) Transforming growth factor-β isoform expression in human ovarian tumours. Eur J Cancer 33:2397-2403
6. Berger AE, Davis JE, Cresswell P (1982) Monoclonal antibody to HLA-A3. Hybridoma 1:87-90
7. Berger S, Siegert A, Denkert C, Kobel M, Hauptmann S (2001) Interleukin-10 in serous ovarian carcinoma cell lines. Cancer Immunol Immunother 50:328-333
8. Brasseur F, Marchand M, Vanwijck R, Herin M, Lethe B, Chomez P, Boon T (1992) Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors. Int J Cancer 52:839-841
9. Brunetti M, Colasante A, Mascetra N, Piantelli M, Musiani P, Aiello FB (1998) IL-10 synergizes with dexamethasone in inhibiting human T cell proliferation. J Pharmacol Exp Ther 285:915-919
10. Buick RN, Pullano R, Trent JM (1985) Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45:3668-3676
11. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949
12. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C et al (1994) Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 40:360-369
13. De Smet C, Lurquin C, Van der Bruggen P, De Plaen E, Brasseur F, Boon T (1994) Sequence and expression pattern of the human MAGE2 gene. Immunogenetics 39:121-129
14. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA (1994) In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54:1071-1076
15. Ellis SA, Taylor C, McMichael A (1982) Recognition of HLA-B27 and related antigen by a monoclonal antibody. Hum Immunol 5:49-59
16. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117
17. Fogh J, Tremple G (1975) New human tumor cell lines. In: Fogh J (ed) Human tumor cell lines in vitro. Plenum Press, New York, pp 115-141
18. Fogh J, Wright WC, Loveless JD (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J Natl Cancer Inst 58:209-214
19. Furlong MT, Hough CD, Sherman-Baust CA, Pizer ES, Morin PJ (1999) Evidence for the colonic origin of ovarian cancer cell line SW626. J Natl Cancer Inst 91:1327-1328
20. Gillespie AM, Rodgers S, Wilson AP, Tidy J, Rees RC, Coleman RE, Murray AK (1998) MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue. Br J Cancer 78:816-821
21. Gordinier ME, Zhang HZ, Patenia R, Levy LB, Atkinson EN, Nash MA, Katz RL, Platsoucas CD, Freedman RS (1999) Quantitative analysis of transforming growth factor β1 and 2 in ovarian carcinoma. Clin Cancer Res 5:2498-2505
22. Gotlieb WH, Abrams JS, Watson JM, Velu TJ, Berek JS, Martinez-Maza O (1992) Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4:385-390
23. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, Whang-Peng J, Rogan AM, Green WR, Ozols RF (1983) Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43:5379-5389
24. Haskill S, Becker S, Fowler W, Walton L (1982) Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumour and ascites material. Br J Cancer 45:728-736
25. Hogan KT, Coppola MA, Gatlin CL, Thompson LW, Shabanowitz J, Hunt DF, Engelhard VH, Ross MM, Slingluff CL (2004) Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T lymphocyte reactivity to melanoma. Cancer Res 64:1157-1163
26. Jager D, Jager E, Knuth A (2001) Immune responses to tumour antigens: Implications for antigen specific immunotherapy of cancer. J Clin Pathol 54:669-674
27. Kabawat SE, Bast RC Jr, Welch WR, Knapp RC, Bhan AK (1983) Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer 32:547-554
28. Karlan BY, Amin W, Band V, Zurawski VR, Littlefield BA (1988) Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol Oncol 31:103-112
29. Kim DK, Lee TV, Castilleja A, Anderson BW, Peoples GE, Kudelka AP, Murray JL, Sittisomwong T, Wharton JT, Kim JW, Ioannides CG (1999) Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res 19:2907-2916
30. Kuppen PJK, Schuitemaker H, van't Veer LJ, de Bruijn EA, van Oosterom AT, Schrier PI (1988) Cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 48:3355-3359
31. Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJLM (1998) Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 29:491-497
32. Lau DHM, Lewis AD, Ehsan MN, Sikic BI (1991) Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res 51:5181-5187
33. Maier JA, Voulalas P, Roeder D, Maciag T (1990) Extension of the life-span of human endothelial cells by an interleukin-1 alpha antisense oligomer. Science 249:1570-1574
34. Makin CA, Bobrow LG, Bodmer WF (1984) Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin Pathol 37:975-983
35. Moll R, Franke WW, Schiller DL (1982) The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors, and cultured cells. Cell 31:11-24
36. Mule JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA (1988) Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26:95-100
37. Nash MA, Lenzi R, Edwards CL, Kavanagh JJ, Kudelka AP, Verschraegen CF, Platsoucas CD, Freedman RS (1998) Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines. Clin Exp Immunol 112:172-180
38. Negus RP, Stamp GW, Hadley J, Balkwill FR (1997) Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150:1723-1734
39. Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187-207
40. Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen Y-T, Driscoll D, Sood A, Lele S, Old LJ (2003) NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 63:6076-6083
41. Parham P, Barnstable CJ, Bodmer WF (1979) Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,b,c, antigens. J Immunol 123:342-349
42. Parham P, Brodsky FM (1981) Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 3:277-299
43. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A (2002) Cancer immunotherapy with peptide-based vaccines: What have we achieved? Where are we going? J Natl Cancer Inst 94:805-818
44. Peoples GE, Anderson BW, Fisk B, Kudelka AP, Wharton JT, Ioannides CG (1998) Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Ann Surg Oncol 5:743-750
45. Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT, Ioannides CG (1999) Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin Cancer Res 5:4214-4223
46. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 92:432-436
47. Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D, Freedman RS (2003) Immune responses to human tumors: development of tumor vaccines. Anticancer Res 23:1969-1996
48. Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson AM, Provencher DM, Lounis H, Champoux L, Tetrault M, Manderson EN, Wang JC, Eydoux P, Savoie R, Tonin PN, Mes-Masson AM (2000) Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36:357-361
49. Ranges GE, Figari IS, Espevik T, Palladino MA (1987) Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J Exp Med 166:991-998
50. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli GC, Cerottini JC (2000) Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins in the MAGE-A family. Int J Cancer 86:749-751
51. Rosenberg SA (1999) A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-287
52. Russo C, Ng AK, Pellegrino MA, Ferrone S (1983) The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics 18:23-35
53. Saalbach A, Anderegg U, Bruns M, Schnabel E, Herrmann K, Haustein UF (1996) Novel fibroblast-specific monoclonal antibodies: properties and specificities. J Investig Dermatol 106:1314-1319
54. Saalbach A, Aust G, Herrmann K, Anderegg U (1997) The fibroblast-specific mab AS02: a novel tool for detection and elimination of human fibroblasts. Cell Tissue Res 290:593-599
55. Santin AD, Bellone S, Ravaggi A, Roman J, Smith CV, Pecorelli S, Cannon MJ, Parham GP (2001) Increased levels of interleukin-10 and transforming growth factor-β in the plasma and ascitic fluid of patients with advanced ovarian cancer. Br J Obstet Gynaecol 108:804-808
56. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Smith CV, Pecorelli S, Radominska-Pandya A, Cannon MJ, Parham GP (2001) Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol Obstet Invest 51:254-261
57. Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3-13
58. Slingluff CL Jr., Hunt DF, Engelhard VH (1994) Direct analysis of tumor-associated peptide antigens. Curr Opin Immunol 6:733-740
59. Smedts F, Ramaekers F, Robben H, Pruszczynski Van Muijen G, Lane B, Leigh I, Vooijs P (1990) Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia. Am J Pathol 136:657-668
60. Stimpfl M, Schmid BC, Schiebel I, Tong D, Leodolter S, Obermair A, Zeillinger R (1999) Expression of mucins and cytokeratins in ovarian cancer cell lines. Cancer Lett 145:133-141
61. Thomas DA, Massague J (2005) TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8:369-380
62. Toutirais O, Chartier P, Dubois D, Bouet F, Leveque J, Catros-Quemener V, Genetet N (2003) Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 14:246-255
63. Wallick SC, Figari IS, Morris RE, Levinson AD, Palladino MA (1990) Immunoregulatory role of transforming growth factor β (TGF-β) in development of killer cells: comparison of active and latent TGF-β1. J Exp Med 172:1777-1784
64. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA (1998) A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161:3598-3606
65. Yamada A, Kataoka A, Shichijo S, Kamura T, Imai Y, Nishida T, Itoh K (1995) Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors. Int J Cancer 64:388-393
66. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213